| Followers | 209 |
| Posts | 39222 |
| Boards Moderated | 4 |
| Alias Born | 08/30/2018 |
Tuesday, February 04, 2025 1:02:30 PM
ACONW ☝️🤑☝️
Bullish
Recent ACON News
- Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment • GlobeNewswire Inc. • 05/07/2026 10:00:00 AM
- Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. • GlobeNewswire Inc. • 05/06/2026 10:00:00 AM
- Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine • GlobeNewswire Inc. • 05/05/2026 10:00:00 AM
- Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption • GlobeNewswire Inc. • 04/30/2026 10:00:00 AM
- Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan • GlobeNewswire Inc. • 04/28/2026 10:00:00 AM
- Aclarion Announces $2.5 Million Stock Repurchase Plan • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain • GlobeNewswire Inc. • 04/16/2026 10:47:04 AM
- Aclarion Receives Pinnacle Award for AI Innovation • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Aclarion Announces Agreement with Weill Cornell Medicine • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. • ACCESS Newswire • 03/24/2026 12:00:00 PM
- Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan • GlobeNewswire Inc. • 03/19/2026 01:25:40 PM
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts • GlobeNewswire Inc. • 03/19/2026 10:00:00 AM
- Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet • GlobeNewswire Inc. • 03/17/2026 10:00:00 AM
- Aclarion CEO Brent Ness to Attend LSI USA 2026 • GlobeNewswire Inc. • 03/12/2026 10:00:00 AM
- Aclarion Publishes 2026 Shareholder Letter from the Chairman • GlobeNewswire Inc. • 02/05/2026 11:00:00 AM
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation • GlobeNewswire Inc. • 02/03/2026 11:00:00 AM
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 • GlobeNewswire Inc. • 01/13/2026 11:00:00 AM
- Aclarion shares surge after sharp rise in Q4 Nociscan usage • IH Market News • 01/08/2026 03:30:17 PM
- Aclarion Provides 2025 Update and 2026 Corporate Outlook • GlobeNewswire Inc. • 01/08/2026 11:00:00 AM
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data • GlobeNewswire Inc. • 01/06/2026 11:00:00 AM
- Aclarion Shares Move Higher After Nociscan Highlighted in Spine Surgery Journal • IH Market News • 12/04/2025 03:58:32 PM
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) • GlobeNewswire Inc. • 12/04/2025 01:00:00 PM
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. • GlobeNewswire Inc. • 12/02/2025 01:00:00 PM
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion • GlobeNewswire Inc. • 11/05/2025 11:00:00 AM
